Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0042-1745833
Recurrence Rate of Giant-Cell Tumor Treated by Curettage and Cementation
Article in several languages: español | English![](https://www.thieme-connect.de/media/10.1055-s-00033425/202201/lookinside/thumbnails/10-1055-s-0042-1745833_2100006_en-1.jpg)
Abstract
Objective To identify the recurrence rate of giant-cell tumor (GCT) in patients treated by curetage and adjuvant therapy with polymethil metacrylate with a minimum follow-up of 3 years.
Methods Observational and retrospective cohort with patients with diagnoses of Enneking stages 1 and 2 GCT treated through intralesional curetage and cementation between 1981 and 2011. Age, gender, anatomic location and relapse period were recorded. The data was analyzed with measures of central tendency and dispersion (standard deviation) for the quantitative variables, percentages for the qualitative variables.
Results Between 1981 and 2011 375 cases of GCT were identified, 141 (36.7%) of which were treated by this method. The follow-up ranged from 48 to 240 months, the age was of 27 ± 9 years, 45% of the patients were female, and 55%, male, with a female:male ratio of about 1.2:1. The tibia was the most frequent affected bone (38%), followed by the femur (32%), the humerus (16%), and the radius (10%). The resection thecnique was intralesional curetage in about 88.6% of the cases, and marginal resection in the remaining cases. Pathologic fracture was present in approximately 15.7%, and recurrence occurred in approximately 12.7%.
Discussion We demonstrated that this treatment method decreases the risk of recurrence due to the local adjuvant effects of acrylic cementation. Recurrence events occur in the first two years after resection. However, some authors defend that the surgical margin is the only factor that influences the risk of local recurrence. The extraosseus extension of GCT is not a contraindication to perform intralesional curetage or to prescribe the adjuvant treatment with polymethyl metacrylate.
Conclusions We reported a recurrence rate similar to that of the literature, and this is a feasible resource for limb reconstruction.
Publication History
Received: 10 March 2021
Accepted: 19 August 2021
Article published online:
20 May 2022
© 2022. Sociedad Chilena de Ortopedia y Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referencias
- 1 Kafchitsas K, Habermann B, Proschek D, Kurth A, Eberhardt C. Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence. Anticancer Res 2010; 30 (09) 3795-3799
- 2 Jamshidi K, Sami S, Modares-Nejad HR, Jhansoz A. Local recurrence in giant cell tumor of bone: Comparative study of two methods of surgical approach. JRMS 2008; 13 (05) 223-229
- 3 Zuo D, Zheng L, Sun W, Fu D, Hua Y, Cai Z. Contemporary adjuvant polymethyl methacrylate cementation optimally limits recurrence in primary giant cell tumor of bone patients compared to bone grafting: a systematic review and meta-analysis. World J Surg Oncol 2013; 11 (156) 1-7
- 4 Wysocki RW, Soni E, Virkus WW, Scarborough MT, Leurgans SE, Gitelis S. Is intralesional treatment of giant cell tumor of the distal radius comparable to resection with respect to local control and functional outcome?. Clin Orthop Relat Res 2015; 473 (02) 706-715
- 5 Komiya S, Inoue A. Cementation in the treatment of giant cell tumor of bone. Arch Orthop Trauma Surg 1993; 112 (02) 51-55
- 6 Bini SA, Gill K, Johnston JO. Giant cell tumor of bone. Curettage and cement reconstruction. Clin Orthop Relat Res 1995; (321) 245-250
- 7 Persson BM, Ekelund L, Lövdahl R, Gunterberg B. Favourable results of acrylic cementation for giant cell tumors. Acta Orthop Scand 1984; 55 (02) 209-214
- 8 Vidal J, Mimran R, Alliev Y, Goalard JM. Plastie de comblement par metacrylatemethyle traiment de certaines tumeurs osseuses benignes. Montpellier Chir 1969; 15 (04) 389-397
- 9 Wilkins RM, Okada Y, Sim FH, Chao EYS, Gorgki J. Methylmethacrylate replacement of subchondral bone: a biomechanical, biochemical, and morphologic analysis. In: Enneking WF. ed. Limb salvage in oncology. Churchill Livingstone; NewYork: 1987: 479-485
- 10 Leeson MC, Lippitt SB. Therrmal aspects of the use of polymethylmrtacrylate in large metaphyseal defects in bone. Clin Orthop Rel Res 1993; 295: 239-245
- 11 Moreno-Wright E, Moreno-Hoyos LF, Técualt-Gómez R. et al. Utilidad del metilmetacrilato en el tumor de células gigantes óseo. Acta Ortop Mex 2003; 17 (06) 281-286
- 12 Boons HW, Keijser LC, Schreuder HW, Pruszczynski M, Lemmens JA, Veth RP. Oncologic and functional results after treatment of giant cell tumors of bone. Arch Orthop Trauma Surg 2002; 122 (01) 17-23
- 13 Davies AM, Vanel D. Follow-up of musculoskeletal tumors. I. Local recurrence. Eur Radiol 1998; 8 (05) 791-799
- 14 Becker WT, Dohle J, Bernd L. et al; Arbeitsgemeinschaft Knochentumoren. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008; 90 (05) 1060-1067
- 15 Frassica FJ, Sim FH, Pritchard DJ, Chao EY. Subchondral replacement: a comparative analysis of reconstruction with methyl methacrylate or autogenous bone graft. Chir Organi Mov 1990; 75 (1, Suppl): 189-190
- 16 O'Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ. ODonnell RJ. Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994; 76 (12) 1827-1833
- 17 Kivioja AH, Blomqvist C, Hietaniemi K. et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008; 79 (01) 86-93
- 18 Gitelis S, Saiz P, Virkus W, Piasecki P, Shott S. Functional and oncological outcomes for giant cell tumor treated by intralesional excision with joint preservation. J Bone Joint Surg [BR] 2005; 87-B: SUPP III
- 19 Labs K, Perka C, Schmidt RG. Treatment of stages 2 and 3 giant-cell tumor. Arch Orthop Trauma Surg 2001; 121 (1-2): 83-86
- 20 Fraquet N, Faizon G, Rosset P, Phillipeau J, Waast D, Gouin F. Long bones giant cells tumors: treatment by curretage and cavity filling cementation. Orthop Traumatol Surg Res 2009; 95 (06) 402-406
- 21 Zhang Q, Cai Y, Niu X, Hao L. [Curettage plus cement reconstruction for treating giant cell tumor of limbs]. Zhonghua Wai Ke Za Zhi 1999; 37 (12) 730-732
- 22 Balke M, Schremper L, Gebert C. et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008; 134 (09) 969-978
- 23 Portabella to the list: Portabella-Blaria F, Illobre-Yebra J, Orduña-Serra M. Tratamiento del tumor de células gigantes mediante legrado y relleno con cemento acrílico. Revista de Ortopedia y Traumatología 1996; 42: 86-90
- 24 Abat F, Almenara M, Peiró A, Trullols L, Bagué S, Grácia I. Tumor de células gigantes óseo. Noventa y siete casos con seguimiento medio de 12 años. Rev Esp Cir Ortop Traumatol 2015; 59 (01) 59-65
- 25 Wang CS, Lou JH, Liao JS. et al. Recurrence in giant cell tumour of bone: imaging features and risk factors. Radiol Med (Torino) 2013; 118 (03) 456-464
- 26 Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011; 469 (02) 591-599
- 27 Lackman RD, Hosalkar HS, Ogilvie CM, Torbert JT, Fox EJ. Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res 2005; 438 (438) 123-127
- 28 Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res 2004; (424) 221-226
- 29 Gao ZH, Yin JQ, Xie XB. et al. Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement. BMC Musculoskelet Disord 2014; 15:330: 1-8
- 30 Rock M. Curettage of giant cell tumor of bone. Factors influencing local recurrences and metastasis. Chir Organi Mov 1990; 75 (1, Suppl): 204-205
- 31 McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am 1986; 68 (02) 235-242
- 32 Dreinhöfer KE, Rydholm A, Bauer HC, Kreicbergs A. Giant-cell tumours with fracture at diagnosis. Curettage and acrylic cementing in ten cases. J Bone Joint Surg Br 1995; 77 (02) 189-193
- 33 Turcotte RE. Giant Cell Tumor of Bone. Orthop Clin N Am 2006; 37: 35-51
- 34 Gambini A, Di Giorgio L, Valeo M, Trinchi R, Marzolini M, Mastantuono M. Giant cell tumor of bone: effect of different surgical techniques and adjuvants on local recurrence rate. J Orthop Traumatol 2003; 3: 126-132
- 35 McGough RL, Rutledge J, Lewis VO, Lin PP, Yasko AW. Impact severity of local recurrence in giant cell tumor of bone. Clin Orthop Relat Res 2005; 438 (438) 116-122